<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00211068</url>
  </required_header>
  <id_info>
    <org_study_id>CR004408</org_study_id>
    <secondary_id>EPO-IMU-403</secondary_id>
    <nct_id>NCT00211068</nct_id>
  </id_info>
  <brief_title>A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa</brief_title>
  <official_title>Retrospective Case-control Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect historical occurrences of risk factors that are
      potentially associated with the development of anti-erythropoietin (EPO) antibody positive
      pure red cell aplasia (PRCA) in participants with chronic kidney disease who have been
      recently treated with epoetin alfa (EPREX).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter (study conducted at multiple sites), case-control (study that compare
      individuals with a disease or condition [cases] to a group of individuals without the disease
      or condition [controls] to determine the possible factor which increased disease incidence),
      retrospective (a study in which the participants are identified and then followed backward,
      as time passes) study. Retrospective risk factor data will be collected for control
      participants matched to the subset of participants in Protocol EPO-IMU-301 identified as
      having chronic kidney disease and anti-EPO antibody positive PRCA that began while the
      participant was receiving treatment with EPREX (index participants). For each index
      participant, up to 4 matched non-PRCA control participants with chronic kidney disease will
      be enrolled in this study. Approximately 600 control participants will be enrolled in this
      study. Control participants will be selected from the same site as the index participant and
      the data will be collected from the date closest to the reference date (loss of efficacy
      [drop in hemoglobin of greater than 2 g/dL/month] was first seen) that the control
      participant satisfies all study inclusion and exclusion criteria. The optional
      pharmacogenomic part (testing for polymorphisms and haploid types of the erythropoietin gene)
      will be recorded for the control participants who will sign the pharmacogenomics part of the
      study. No drug administration or treatment will be mandated by this study. Safety evaluation
      will include assessment of adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Study medication-related risk factors: Number of participants who received Human Serum Albumin (HSA) containing drug</measure>
    <time_frame>1 year prior to the reference date</time_frame>
    <description>The reference date is the day on which Loss of Efficacy (LOE) was first suspected, where LOE is the date that a drop in hemoglobin of greater than 2 g/dL/month was first seen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study medication-related risk factors: Number of participants who received HSA-free drug</measure>
    <time_frame>1 year prior to the reference date</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Study medication administration-related risk factors: Number of participants who received epoetin alfa intravenously</measure>
    <time_frame>1 year prior to the reference date</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Study medication administration-related risk factors: Number of participants who received epoetin alfa subcutaneously</measure>
    <time_frame>1 year prior to the reference date</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Study medication administration-related risk factors: Number of participants who self-administered epoetin alfa</measure>
    <time_frame>1 year prior to the reference date</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Study medication administration-related risk factors: Number of participants who administered epoetin alfa in hospital or in clinic</measure>
    <time_frame>1 year prior to the reference date</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Study medication administration-related risk factors: Number of participants with the duration of epoetin alfa treatment</measure>
    <time_frame>1 year prior to the reference date</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Study medication administration-related risk factors: Number of participants with the duration of other recombinant human erythropoietins (r-HuEPOs) treatment</measure>
    <time_frame>1 year prior to the reference date</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Study medication administration-related risk factors: Number of participants with exposure to epoetin alfa</measure>
    <time_frame>1 year prior to the reference date</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Study medication administration-related risk factors: Number of participants with exposure to other r-HuEPOs</measure>
    <time_frame>1 year prior to the reference date</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Study medication administration-related risk factors: Number of participants with frequency of epoetin alfa dosing</measure>
    <time_frame>6 months prior to the reference date</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Study medication administration-related risk factors: Number of participants with frequency of other r-HuEPOs dosing</measure>
    <time_frame>6 months prior to the reference date</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant-related risk factors: Number of participants according to age</measure>
    <time_frame>1 year prior to the reference date</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant-related risk factors: Number of participants according to sex</measure>
    <time_frame>1 year prior to the reference date</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant-related risk factors: Number of participants according to race</measure>
    <time_frame>1 year prior to the reference date</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant-related risk factors: Number of participants according to underlying diagnosis of chronic kidney disease</measure>
    <time_frame>1 year prior to the reference date</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant-related risk factors: Number of participants according to type of renal replacement therapy (if any at the time of the reference date)</measure>
    <time_frame>1 year prior to the reference date</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant-related risk factors: Number of participants with history of malnutrition</measure>
    <time_frame>1 year prior to the reference date</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant-related risk factors: Number of participants with history of autoimmune disease or positive results of autoimmune testing</measure>
    <time_frame>1 year prior to the reference date</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant-related risk factors: Number of participants with history of immune dysregulation</measure>
    <time_frame>1 year prior to the reference date</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant-related risk factors: Number of participants with uncontrolled hyperparathyroidism</measure>
    <time_frame>1 year prior to the reference date</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant-related risk factors: Number of participants with uncontrolled hypothyroidism</measure>
    <time_frame>1 year prior to the reference date</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant-related risk factors: Number of participants with history of malignancy</measure>
    <time_frame>5 years prior to the reference date</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant-related risk factors: Number of participants with history of viral infection</measure>
    <time_frame>1 year prior to the reference date</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant-related risk factors: Number of participants with history of vaccination</measure>
    <time_frame>1 year prior to the reference date</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant-related risk factors: Number of participants with immunosuppressive/immunomodulatory therapy</measure>
    <time_frame>1 year prior to the reference date</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant-related risk factors: Number of participants with history of frequent transfusions</measure>
    <time_frame>1 year prior to the reference date</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant-related risk factors: Number of participants with treatment with other subcutaneous medications</measure>
    <time_frame>1 year prior to the reference date</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant-related risk factors: Number of participants with treatment with other recombinant human proteins</measure>
    <time_frame>1 year prior to the reference date</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant-related risk factors: Number of participants who received other concomitant therapy</measure>
    <time_frame>1 year prior to the reference date</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Human leukocyte antigen (HLA) typing</measure>
    <time_frame>1 year prior to the reference date</time_frame>
    <description>The optional pharmacogenomic (use of genetic information to predict whether the study medication will help make a patient well or ill) part of the study will test for polymorphisms and haploid types of the erythropoietin gene. HLA typing will be recorded for the control participants who will sign the pharmacogenomics part of the study.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">124</enrollment>
  <condition>Pure Red-cell Aplasia</condition>
  <arm_group>
    <arm_group_label>Epoetin alfa</arm_group_label>
    <description>Four control patients will be matched to each index patients enrolled in protocol EPO-IMU-301 identified as having chronic kidney disease and an immune-mediated cause of pure red cell aplasia (PRCA) indicated by the presence of anti-erythropoietin (EPO) antibodies in their serum at the time of loss of efficacy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>This study is an observational study. No medication will be provided or administered to the participants. Participants will receive standard-of-care treatment from their individual physicians.</description>
    <arm_group_label>Epoetin alfa</arm_group_label>
    <other_name>EPREX</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample collected for pharmacogenomic analysis
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants having chronic kidney disease and an immune-mediated cause of pure red cell
        aplasia indicated by the presence of anti-erythropoietin antibodies in their serum at the
        time of loss of efficacy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of anemia due to chronic kidney disease

          -  Pure red cell aplasia (PRCA) associated with erythropoietin-alpha (EPO) treatment

          -  Treatment with EPO for a minimum of 2 months occurring within more or less 3 months of
             the reference date (date of loss of efficacy [drop in hemoglobin of greater than 2
             g/dL/month] was first observed)

        Exclusion criteria

          -  History of and information related to past exposure to EPO not available

          -  History of PRCA or anti-EPO antibody positive status before or after the reference
             date
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Pharmaceutical Research and Development, L. L. C. Clinical trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sorocaba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bois Guillaume Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grenoble Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes Cedex 2</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orleans Cedex 2</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris Cedex 20</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tvnsberg</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bloemfontein</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Karlshamn</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm N/A</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trollh√§ttan</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vlissingen</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chelmsford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omagh N/A</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westcliff-On-Sea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>France</country>
    <country>Norway</country>
    <country>South Africa</country>
    <country>Sweden</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>April 29, 2013</last_update_submitted>
  <last_update_submitted_qc>April 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pure red-cell aplasia</keyword>
  <keyword>Chronic kidney failure</keyword>
  <keyword>Epoetin alfa (Eprex)</keyword>
  <keyword>Erythropoietin</keyword>
  <keyword>Kidney disease</keyword>
  <keyword>Anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Red-Cell Aplasia, Pure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

